Home - Products - Cell Cycle/DNA Damage - CDK - Avotaciclib

Avotaciclib

CAS No. 1983983-41-0

Avotaciclib( —— )

Catalog No. M35116 CAS No. 1983983-41-0

Avotaciclib (BEY1107) is a potent, orally active cyclin-dependent kinase 1 (CDK1) inhibitor, suitable for research in locally advanced or metastatic pancreatic cancer.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
5MG	273	In Stock
10MG	433	In Stock
25MG	712	In Stock
50MG	986	In Stock
100MG	1321	In Stock
200MG	Get Quote	In Stock
500MG	2651	In Stock
1G	Get Quote	In Stock

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Avotaciclib
Note

Research use only, not for human use.
Brief Description

Avotaciclib (BEY1107) is a potent, orally active cyclin-dependent kinase 1 (CDK1) inhibitor, suitable for research in locally advanced or metastatic pancreatic cancer.
Description

Avotaciclib (BEY1107) is a potent and orally active inhibitor of cyclin dependent kinase 1 (CDK1). Avotaciclib can be used for the research of locally advanced or metastatic pancreatic cancer.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Cell Cycle/DNA Damage
Target

CDK
Recptor

CDK
Research Area

——
Indication

——

Chemical Information

CAS Number

1983983-41-0
Formula Weight

281.27
Molecular Formula

C13H11N7O
Purity

>98% (HPLC)
Solubility

——
SMILES

OC1=C(N=C(C=C1)C2=NC(N)=NC=C2)C3=NC(N)=NC=C3
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1. Seufferlein T, et, al. Phase I Trials in Pancreatic Cancer. Translational Pancreatic Cancer Research pp 219-232.

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

AZA197

AZA197 (AZA-197) is a selective Cdc42 inhibitor. It acts by inhibiting primary colon cancer growth and prolonging survival in a preclinical mouse xenograft model by downregulation of PAK1 activity.
CDK1-IN-2

CDK1-IN-2 (cdk1 inhibitor 2) is a CDK1 inhibitor with IC50 of 5.8 μM. A broad-spectrum kinase profiling of CDK1-IN-2 revealed nonselective inhibition of several kinases.
CYC065

CYC065 is a derivative of seliciclib and second generation CDK inhibitor that is mainly active on CDK2/5/9.

Sign In Join Free